Brexpiprazole in Patients With Schizophrenia
Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Parnu, Estonia
- EE002
-
Tallinn, Estonia
- EE001
-
-
-
-
-
Choroszcz, Poland
- PL002
-
Choroszcz, Poland
- PL005
-
Gdansk, Poland
- PL004
-
-
-
-
-
Brasov, Romania
- RO004
-
Bucharest, Romania
- RO011
-
Bucuresti, Romania
- RO007
-
Bucuresti, Romania
- RO012
-
Iasi, Romania
- RO010
-
Pitesti, Romania
- RO006
-
-
-
-
-
Arkhangelsk, Russian Federation
- RU001
-
Moscow, Russian Federation
- RU008
-
Rostov on Don, Russian Federation
- RU015
-
Saratov, Russian Federation
- RU002
-
St. Petersburg, Russian Federation
- RU004
-
St. Petersburg, Russian Federation
- RU005
-
St. Petersburg, Russian Federation
- RU013
-
-
-
-
-
Belgrade, Serbia
- RS003
-
Belgrade, Serbia
- RS001
-
Kragujevac, Serbia
- RS002
-
Novi Knezevac, Serbia
- RS004
-
-
-
-
-
Liptovsky Mikulas, Slovakia
- SK001
-
-
-
-
-
Dnipropetrovsk, Ukraine
- UA012
-
Geikivka, Ukraine
- UA004
-
Glevakha, Ukraine
- UA007
-
Kherson, Ukraine
- UA005
-
Kyiv, Ukraine
- UA008
-
Lviv, Ukraine
- UA009
-
Smila, Ukraine
- UA002
-
Vinnytsya, Ukraine
- UA003
-
-
-
-
California
-
Anaheim, California, United States
- US010
-
Cerritos, California, United States
- US020
-
Escondido, California, United States
- US009
-
Garden Grove, California, United States
- US022
-
Long Beach, California, United States
- US018
-
San Diego, California, United States
- US011
-
-
District of Columbia
-
Washington, District of Columbia, United States
- US021
-
-
Florida
-
Kissimmee, Florida, United States
- US004
-
North Miami, Florida, United States
- US015
-
-
Louisiana
-
Lake Charles, Louisiana, United States
- US019
-
-
Missouri
-
St. Louis, Missouri, United States
- US016
-
-
New York
-
Cedarhurst, New York, United States
- US002
-
-
South Carolina
-
Charleston, South Carolina, United States
- US005
-
-
Texas
-
Austin, Texas, United States
- US003
-
Austin, Texas, United States
- US012
-
Dallas, Texas, United States
- US001
-
Dallas, Texas, United States
- US013
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient has completed the lead-in study 14644A.
- The patient is judged to potentially benefit from 52-week treatment with brexpiprazole according to the clinical opinion of the investigator.
- The patient agrees to protocol-defined use of effective contraception.
Exclusion Criteria:
- The patient has been diagnosed with a primary psychiatric disorder other than schizophrenia during Study 14644A.
- The patient has a clinically significant unstable illness diagnosed during Study 14644A.
- The patient, in the opinion of the investigator or according to Columbia-Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
- The patient has an abnormal ECG or other abnormal ECG tests that are, in the investigator's opinion, clinically significant.
- The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.
Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brexpiprazole
|
1 to 4 mg/day, once daily, tablets, orally.
The patients received 2 mg/day brexpiprazole on Day 1.
If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety and Tolerability
Time Frame: Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)
|
Number of treatment-emergent adverse events (TEAEs)
|
Up to 52 weeks and a safety follow-up by telephone contact or clinic visit after 30 days after the last dose of investigational medicinal product (IMP)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Correll CU, He Y, Therrien F, MacKenzie E, Meehan SR, Weiss C, Hefting N, Hobart M. Effects of Brexpiprazole on Functioning in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. J Clin Psychiatry. 2022 Mar 1;83(2):20m13793. doi: 10.4088/JCP.20m13793.
- Marder SR, Meehan SR, Weiss C, Chen D, Hobart M, Hefting N. Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies. Schizophr Bull Open. 2021 May 1;2(1):sgab014. doi: 10.1093/schizbullopen/sgab014. eCollection 2021 Jan.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14644B
- 2012-002705-21 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.